Antioxidant vitamins and prevention of cardiovascular disease: Laboratory, epidemiological and clinical trial data

Pharmacological Research

Volumn 40, Issue 3, 1999, Pages 227-238

  Marchioli, R ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Antioxidant; Atherosclerosis; Ischaemic heart disease; Review

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE;

ATHEROSCLEROSIS; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET SUPPLEMENTATION; HUMAN; PRIORITY JOURNAL; REVIEW; VITAMIN INTAKE;

EID: 0032831884     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1999.0480     Document Type: Article

References (111)

1. th century saga. Lancet 1998; 352: 1771-4.
2. GISSI-Avoidable Delay Study Group. Epidemiology of avoidable delay in the care of acute myocardial infarction patients in Italy: a GISSI generated study. Arch Intern Med 1995; 155: 1481-8.
3. Fox R. Trends in cardiovascular mortality in Europe. Circulation 1997; 96: 3817-18.
4. Sans S, Kesteloot H, Kromhout D, on behalf of the Task Force of the European society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. The burden of cardiovascular diseases mortality in Europe. Eur Heart J 1997; 18: 1231-48.
5. Kesteloot H. Nutrition and health. Eur Heart J 1992; 13: 120-8.
6. Bobak M, Marmot M. East-West mortality divide and its potential explanations: proposed research agenda. Br Med J 1996; 312: 421-5.
7. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436-42.
8. Oliver MF. Antioxidant nutrients, atherosclerosis, and coronary heart disease. Br Heart J 1995; 73: 299-301.
9. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease: A critical review of epidemiologic and clinical trial data. Ann Intern Med 1995; 123: 860-72.
10. Morrow DA. Where are we with vitamin E? J Thromb Throbolysys 1998; 5: 209-14.
11. Lonn E, Yusuf S. Is there a role for antioxidant vitamins in the prevention of cardiovascular disease? An update on epidemiological and clinical trials data. Can J Cardiol 1997; 13: 957-65.
12. Omenn GS. Interpretation of the linxian vitamin supplement chemoprevention trials. Epidemiology 1998; 9: 1-4.
13. Gaziano JM. Antioxidant vitamins and coronary heart disease risk. Am J Med 1994; 97: 18S-21S.
14. Stephens N. Anti-oxidant therapy for ischaemic heart disease: where do we stand? Lancet 1997; 349: 1710-11.
15. Hoffman RM, Garewal HS. Antioxidants and the prevention of coronary heart disease. Arch Intern Med 1995; 155: 241-6.
16. Nestel PJ. Controlling coronary risk through nutrition. Can J Cardiol 1995; 11: 9G-14G.
17. Mancini M, Parfitt VJ, Rubba P. Antioxidants in the Mediterranean diet. Can J Cardiol 1995; 11: 105G-9G.
18. Stampfer MJ, Rimm EB. Epidemiologic evidence for vitamin E in prevention of cardiovascular disease. Am J Clin Nutr 1995; 62: 1365S-9S.
19. Marchioli R, Di Pasquale A. Il quadro di riferimento biochimico, farmacologico, epidemiologico del GISSI-Prevenzione. G Ital Cardiol 1993; 23: 933-64.
20. Onori L, Ciccocioppo R, Saltarelli P et al. Metaboliti reattivi dell'ossigeno in medicina interna. Federazione Medica 1992; 5: 31-38.
21. Marchioli R, Schweiger C. Vitamine antiossidanti nella prevenzione primaria e secondaria della cardiopatia ischemica. In: Cardiologia. Scientific Press Ed, 1994: 551-69.
22. Marchioli R. Antiossidanti farmaci. Enciclopedia Medica Italiana, Agg 11, Tomi I, 1998: 474-90.
23. Steinberg D: Antioxidants and atherosclerosis. A current assessment. Circulation 1991; 84: 1420-5.
24. Duthie GG, Wahle KWJ, James WPT. Oxidants, antioxidants and cardiovascular disease. Nutr Res Rev 1989; 2: 51-62.
25. Steinberg D, Workshop Participants. Antioxidants in the prevention of human atherosclerosis. Circulation 1992; 85: 2337-44.
26. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
27. Duthie GG, Wahle KWJ, James WPT: Oxidants, antioxidants and cardiovascular disease. Nutr Res Rev 1989; 2: 51-62.
28. Sullivan JL. Antioxidants and coronary heart disease. Lancet 1991; 337: 432-3.
29. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13: 341-90.
30. Steinberg D, Witztum JL. Lipoproteins and atherogenesis. Current Concepts. J Am Med Assoc 1990; 264: 3047-52.
31. Ross R. The pathogenesis of atherosclerosis. In: Braunwald E, eds. Heart disease. A textbook of cardiovascular medicine. 4th ed. Philadelphia: WB Saunders Company, 1992: 1106-24.
32. Burton GW, Traber MG. Vitamin E: antioxidant activity, biokinetics, and bioavailability. Ann Rev Nutr 1990; 10: 357-82.
33. Stampfer MJ, Willett W, Castelli WP, Taylor JO, Fine J, Hennekens CH. Effect of vitamin E on lipids. Am J Clin Pathol 1983; 79: 714-16.
34. Esterbauer H, Dieber-Rotheneder M, Striegl G, Waeg G. Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am J Clin Nutr 1991; 53: 314S-21S.
35. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 1988; 85: 9748-52.
36. Avogaro P, Bon GB, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis 1988; 8: 79-87.
37. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13: 341-90.
38. Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408-16.
39. Quinn MT, Parthasarathy S, Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc Natl Acad Sci USA 1985; 82: 5949-53.
40. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995-8.
41. Frostergard J, Haegerstrand A, Gidlund L, Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991; 90: 119-26.
42. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995; 332: 512-21.
43. Nagano Y, Arai H, Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci USA 1991; 88: 6457-61.
44. Reaven PD, Witztum JL. Comparison of supplementation of RRR-α-tocopherol and racemic α-tocopherol in humans. Effects on lipid levels and lipoprotein susceptibility to oxidation. Arterioscler Thromb 1993; 13: 601-8.
45. Reaven PD, Khouw A, Beltz WF, Parthasarathy S, Witztum JL. Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by β-carotene. Arterioscler Thromb 1993; 13: 590-600.
46. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987; 84: 7725-9.
47. Kita T, Nagano Y, Yokode M et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987; 84: 5928-31.
48. Gey KF, Moser UK, Jordan P, Stähelin HB, Eichholzer M, Lüdin E. Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. Am J Clin Nutr 1993; 57(Suppl): 787S-97S.
49. Jalal I, Freeman DA, Grundy SM. Varying susceptibility of different low density lipoproteins to oxidative modification. Arterioscler Thromb 1191; 11: 482-8.
50. Jalal I, Grundy SM. Influence of antioxidant vitamins on LDL oxidation. Ann NY Acad Sci 1992; 669: 237-48.
51. Jalal I, Grundy SM. Combined supplementation with alpha-tocopherol, ascorbate and beta-carotene inhibits LDL oxidation. Circulation 1992; 86: 462.
52. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988; 241: 215-18.
53. Palinski W, Rosenfeld ME, Yla-Herttuala S et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-6.
54. Salmon S, Maziere C, Theron L et al. Immunological detection of low density lipoproteins modified by malondialdehyde in vitro or in vivo. Biochim Biophys Acta 1987; 920: 215-20.
55. Kleijnen J, Knipschild P, ter Riet G. Vitamin E and cardiovascular disease. Eur J Clin Pharmacol 1989; 37: 541-4.
56. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidised lipoproteins. J Clin Invest 1992; 89: 10-18.
57. Kugiyama K, Kerns SA, Morriset JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-2.
58. Kugiyama K, Ohgushi M, Sugiyama S et al. Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res 1992; 71: 1422-8.
59. Anderson TJ, Meredith IT, Charbonneau F et al. Endothelium-dependent coronary vasomotion relates to susceptibility of LDL to oxidation in humans. Circulation 1996; 93: 1647-50.
60. Faruqi R, de la Motte C, DiCorleto PE. Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured endothelial cells. J Clin Invest 1994; 94: 592-6.
61. Plane F, Jacobs M, McManus D, Bruckdorfer KR. Probucol and other antioxidants prevent the inhibition of endothelium-dependent arterial relaxation by low density lipoproteins. Atherosclerosis 1993; 103: 73-9.
62. 2a is increased in hypercholesterolemia. Arterioscl Thromb Vasc Biol 1997; 17: 3230-5.
63. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscl Thromb Vasc Biol 1997; 17: 2309-15.
64. 2-isoprostane formation. Br J Pharmacol 1996; 118: 1285-93.
65. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Prevention of atherosclerosis: the potential role of antioxidants. Postgrad Med 1995; 98: 175-84.
66. Harats D, Ben-Naim M, Dabach Y et al. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Arterioscler Thromb 1991; 11: 482-8.
67. Babiy AV, Gebicki JM, Sullivan DR et al. Increased oxidability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochem Pharmacol 1992; 43: 995-1000.
68. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. Oxford University Press 1994.
69. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 39: 1-30.
70. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-6.
71. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444-9.
72. Kushi LH, Folsom AR, Prineas RJ et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334: 1156-62.
73. Knekt P, Reunanen A, Jarvinen R et al. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994; 139: 1180-9.
74. Gaziano JM, Manson JE, Branch LG et al. Dietary beta-carotene and decreased cardiovascular mortality in an elderly cohort (abstract). J Am Coll Cardiol 1992; 19(Suppl A): 377A.
75. Gey KF, Moser UK, Jordan P, Stähelin HB, Eichholzer M, Lüdin E. Increased risk of cardiovascular disease at suboptimal plasma concetrations of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. Am J Clin Nutr 1993; 57(Suppl): 787S-97S.
76. Morris DL, Krichevsky SB, Davis CE. Serum carotenoids and coronary heart disease: The lipid research clinics coronary primary prevention trial and follow-up study. J Am Med Assoc 1994; 272: 1439-41.
77. Kardinaal AFM, Kok FJ, Ringstad J, Gomez-Aracena J, Mazaev VP, Kohlmeier L et al. Antioxidants in adipose tissue and risk of myocardial infarction: the Euramic study. Lancet 1993; 342: 1379-84.
78. Salonen JT, Salonen R, Penttilä I et al. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol 1985; 56: 226-31.
79. Kok FJ, de Bruijn AM, Vermeeren R et al. Serum selenium, vitamin antioxidants, and cardiovascular mortality: a 9-year follow-up study in the Netherlands. Am J Clin Nutr 1987; 45: 462-8.
80. Street DA, Comstock GW, Salkeld RM et al. Serum antioxidants and myocardial infarction: Are low levels of carotenoids and α-tocopherol risk factors for myocardial infarction? Am J Clin Nutr 1994; 90: 1154-61.
81. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
82. Omenn GS, Goodman GE, Thornquist MD et al. Effects of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-5.
83. Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-9.
84. Gaziano JM, Manson JE, Ridker PM, Buring JE, Hennekens CH. Beta carotene therapy, for chronic stable angina (Abstract 0796). Circulation 1990; 82(Suppl III): 201.
85. Greenberg ER, Baron JA, Tosteson TD et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 1994; 331: 141-7.
86. Greenberg ER, Baron JA, Stukel TA et al. A clinical trial of beta-carotene to prevent basal-cell and squamous-cell cancers of the skin. The skin Cancer Prevention Study Group. N Engl J Med 1990; 323: 789-95.
87. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992; 3: 194-202.
88. Enstrom JE, Kanim LE, Breslow L. The relationship between vitamin C intake, general health practices, and mortality in Alameda County, California. Am J Public Health 1986; 76: 1124-30.
89. Gale CR, Martyn CN, Winter PD et al. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. Br Med J 1995; 310: 1563-6.
90. Gey KF, Stähelin HB, Puska P, Evans A. Relationship of plasma level of vitamin C to mortality from ischemic heart disease. Ann NY Acad Sci 1987; 498: 110-23.
91. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53: 326S-34S.
92. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-92.
93. Wilson TS, Datta SB, Murrel JS et al. Relation of vitamin C levels to mortality in a geriatric hospital: a study of the effect of vitamin C administration. Age Aging 1973; 2: 163-71.
94. Salonen JT, Salonen R, Seppanen K et al. Relationship of serum selenium and antioxidants to plasma lipoproteins, platelet aggregability and prevalent ischaemic heart disease in Eastern Finnish men. Atherosclerosis 1988; 70: 155-60.
95. Riemersma RA, Oliver M, Elton RA et al. Plasma antioxidants and coronary heart disease: vitamins C and E, and selenium. Eur J Clin Nutr 1990; 44: 143-50.
96. Stringer MD, Görög PG, Freeman A, Kakkar VV. Lipid peroxides and atherosclerosis. Br Med J 1989; 298: 281-4.
97. Riemersma RA, Wood DA, Macintyre CCA, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet 1991; 337: 1-5.
98. DeMaio SJ, King SB, Lembo NJ et al. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA). J Am Coll Nutr 1992; 11: 68-73.
99. Stephens NG, Parsons A, Schofield PM et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-6.
100. Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction the Indian experiment of infarct survival-3). Am J Cardiol 1996; 77: 232-6.
101. Vollset SE, Bjelke E. Does consumption of fruit and vegetables protect against stroke? (letter) Lancet 1983; 2: 742.
102. Marchioli R, Bomba E, Tognoni G. Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease. Lancet 1996; 347: 467-8.
103. Artaud-Wild SM, Connor SL, Sexton G, Connor WE. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. A paradox. Circulation 1993; 88: 2771-9.
104. Hertog MG, Kromhout D, Aravanis C et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the Seven countries Study. Arch Intern Med 1995; 155: 381-6.
105. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993; 342: 1007-11.
106. Marchioli R, Tognoni G. Beneficial effects of statins. Lancet 1996; 348: 1542.
107. Clarke R, Frost C, Collins R, Appleby P, Peto R. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. Br Med J 1997; 314: 112-17.
108. Ebrhaim S, Davey Smith G. Systematic review of randomised controlled trials of multiple interventions for preventing coronary heart disease. Br Med J 1997; 314: 1666-74.
109. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HAW. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. Br Med J 1998; 316: 1213-20.
110. Hu FB, Stampfer MJ, Manson JE, Rimm E, Colditz GA et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 1997; 337: 1491-9.
111. Weindruch R, Sohal RS. Caloric intake and aging. N Engl J Med 1997; 337: 987-94.